Broncus Technologies Inc., a Mountain View, Calif.-based developer of medical devices for emphysema and other lung diseases, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol LUNG, with Lehman Brothers and Bear Stearns serving as co-lead underwriters.
The company has raised around $73 million in total VC funding since 1997, from firms like HBM Partners (26.2% pre-IPO stake), Abingworth Management (15.3%), Menlo Ventures (12.7%), Boston Scientific Corp. (7.9%) and SightLine Partners (7.6%), Bio*One, Charter Ventures, JAIC America, Oakwood Medical Investors, Pac-Link Management, Pequot Ventures and Saratoga Ventures. www.broncus.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.